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Ying Lu, Edmund K. WallerInterferon (IFN)-g is a pleiotropic cytokine with a central role in innate and adaptive immunity. As a potent
pro-inflammatory and antitumor cytokine, IFN-g is conventionally thought to be responsible for driving cel-
lular immune response. On the other hand, accumulating evidence suggests that IFN-g also has immunosup-
pressive activity. An important role for IFN-g in inhibiting graft-versus-host disease (GVHD) has been
demonstrated in murine models, despite IFN-g being one of the key factors amplifying T cell activation during
the process of acute GVHD (aGVHD), the major complication and cause of post-transplant mortality in al-
logeneic bone marrow transplantation (BMT). At the same time, IFN-g facilitates graft-versus-leukemia
(GVL) activity. Dissociation of GVL effects from GVHD has been the ultimate goal of allogeneic BMT in
the treatment of hematologic malignancies. This paradoxic role of IFN-g makes modulating its activity
a promising strategy to maximize GVL while minimizing GVHD and improve clinical outcomes in BMT. In
this review, the effects of IFN-g on GVHD and GVL are discussed with consideration of the mechanism
of IFN-g action.
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The interferons (IFNs) were originally discovered
as antiviral agents, and were classified into type I and
type II according to receptor specificity and sequence
homology [1,2]. IFN-g is the sole type II IFN, and is
synthesized by CD41 Th1 lymphocytes, CD81 cyto-
toxic lymphocytes, natural killer (NK) cells, B cells,
NKT cells, and antigen-presenting cells (APCs) [3-
7]. The regulation of T cell IFN-g production in-
cludes induction by interleukin (IL)-12 and IL-18
and downregulation by IL-4, IL-10, transforming
growth factor (TGF)-b and glucocorticoids [8-13]. Al-
though the immune system appears to develop nor-
mally in the absence of pathogens, IFN-g knockout
mice showed decreased ability in their resistance to
bacterial, parasitic, and viral infections, suggesting
a pivotal role for IFN-g in the induction of cellular
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6/j.bbmt.2009.07.015activation of donor T cells in pathogenesis of graft-
versus-host disease (GVHD) implicates IFN-g as
a central regulatory cytokine in the initiation and
maintenance of allo-reactivity in allogeneic hemato-
poietic progenitor cell transplantation (HPCT)
[15,16].
During the development of GVHD, IFN-g medi-
ates multiple effects including priming of macrophages
to produce pro-inflammatory cytokines and nitric
oxide (NO) in response to lipopolysaccharide (LPS),
upregulating expression of adhesion molecules, che-
mokines, major histocompatibility (MHC) II antigen
and FAS on APC, resulting in enhanced antigen pre-
sentation and recruitment of effector cells [15-17]. In-
creased serum levels of IFN-gwere associated with the
severity of acute GVHD (aGVHD) in mice and anti-
IFN-g antibodies prevented gastrointestinal (GI)
GVHD in a CBA/ F1mice model [18-21]. Although
all these data demonstrated that IFN-g can amplify
GVHD, IFN-g has been shown to also limit
GVHD, organ transplantation rejection, and autoim-
munity [18,22-26]. This paradoxic effects of IFN-g
on GVHD can be partially explained by the observa-
tion that IFN-g can prevent T cell activation directly
by inducing T cell growth arrest and apoptosis or indi-
rectly by altering the function of dendritic cells (DC),
the most efficient APC population [27-30]. The effect
of IFN-g on the immunologic microenvironment is
also mediated in part by IFN-g-inducible genes that
serve counterregulatory roles in immune activation,1347
Table 1. Impact of Cotransplant Different Donor APC Subsets with HSC and T Cells on Th1/Th2 Polarization Based on
Intracellular Cytokine Staining and Serum Cytokines in Tumor-Bearing Recipient Mice [55]
Donor APC Subsets GVHD GVL Survival IFN-g IL-4 IL-10
BM CD11b- APC No change [ [ [ Y Y
BM CD11b+ APC No change No change No change Y [ [
[/Y indicates increase/decrease compared to recipients transplanted with HSC, T cells, and no APC; HSC, hematopoietic stem cell; GVL, graft-versus-
leukemia; APC, antigen-presenting cells; GVHD, graft-versus-host disease; IFN, interferon, BM, bone marrow.
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ible nitric oxide synthase (iNOS), and heme oxygenase
(HO)-1 that can limit activation of effector T cells
[30-32]. This review summarizes current knowledge
of the role of IFN-g on GVHD and GVL based
primarily on results from murine model systems, but
with attention to potential clinical translation of these
findings.
Role of IFN-g in GVHD and GVL
Effects of exogenous administration of IFN-g
Based on the immunosuppressive effects of IFN-g,
investigators have shown that administration of exog-
enous IFN-g can prevent GVHD in a murine bone
marrow transplantation (BMT)model [24], suggesting
the clinical administration of exogenous IFN-g as
a novel strategy to prevent GVHD in allogeneic hema-
topoietic progenitor cell transplantation (HPCT) [33].
The effect of exogenous IFN-g administration in mu-
rine BMTmodel systems varies by strain, timing of ad-
ministration, and intensity of conditioning, which
suggest in part the reasons for the conflicting results
of the effect of this cytokine on aGVHD [24,34]. For
example, Brok et al. [24] found that high levels of
IFN-g immediately after BMT is crucial for the pre-
vention of GVHD. Treatment with 50,000 U IFN-g
twice weekly for a period of 5 weeks, starting at the
day of BMT, was an optimal treatment protocol to
prevent GVHD in a fully H-2-mismatched BMT
model. A shorter treatment course (1 week with
a higher dose of IFN-g), did not result in significantly
improved survival compared to untreated control ani-
mals. The timing of IFN-g administration was a criti-
cal factor, because a delay of 3 days from the time of
BMT resulted in substantial GVHD-induced mortal-
ity [24]. Similarly, as shown by Szebeni et al. [35], ad-
ministration of IFN-g from day 2 onward had no effect
on GVHD.
Factors that regulate T cell production of IFN-g
The central role of donor T cells in both GVHD
and GVL effects has been demonstrated by the mark-
edly reduced frequency and severity of GVHD but in-
creased leukemia relapse in patients given allografts
stringently depleted of T cells [36]. Different methods
targeting donor T cells have been tested in efforts to
limit GVHD, but while preserve GVL [15,37-42].The administration of IL-12, a potent inducer of
IFN-g production, at the time of allo-BMT had a sig-
nificant protective effect against GVHD, which can be
eliminated by anti-IFN-g antibody or using IFN-g-
deficient T cells [43-45]. Similar results were obtained
from administration of IL-18, another potent inducer
of IFN-g production [46,47].
Of note, growing data has revealed the importance
of both host-type and donor-type APCs in regulating
T cell activity in allogeneic BMT model [48-51].
Our group initially reported that large numbers of
plasmacytoid DC precursors in donor BM are associ-
ated with increased relapse after allogeneic BMT
[52]. Recently, using an allogeneic murine BMT
model (C57BL/6/ B10.BR), the addition of donor
IL-12-producing CD11b2 APC to a graft composed
of purified hematopoietic stem cells (HSC) and T cells
was shown to remarkably improve long-term leuke-
mia-free survival (LFS) without increasing GVHD.
Intriguingly, higher number of IFN-g-producing do-
nor T cells was seen among recipients of CD11b2
APC and all of the beneficial effects of donor
CD11b2 APC on posttransplant survival were abro-
gated when IFN-g knockout mice were used as T
cell donors (Table 1) [53-55]. These data are consis-
tent with other murine models in which IFN-g pro-
duction enhances the GVL activity of donor T cells,
whereas it limits GVHD mortality. In addition,
IFN-g can increase the sensitivity of tumor cells to
CTL activity via upregulation of FAS and major histo-
compatibility complex (MHC) expression [22]. More
recently, Wang et al. [56] reported that IFN-g could
promote lymphohematopoietic graft-versus-host reac-
tions (LGVHR) andGVLwith limitedGVHDeffects.
IFN-g expression by NK and NKT cells
NK cells were initially described as radio-resistant
host cells that mediated graft rejection in lethally irra-
diated F1 mice transplanted with parental type T cell-
depleted BM [57,58]. Recent studies have shown that
NK cells have the dual ability to mediate both BM re-
jection (host NK cells) and to promote engraftment
and GVL activity (donor NK cells). Asai et al. [7]
found that mice injected with activated NK cells of do-
nor type survived longer with less GVHD. Further-
more, administration of activated NK cells resulted
in significant GVL effects as evidenced by increased
survival and fewer lung metastases in mice bearing
Biol Blood Marrow Transplant 15:1347-1353, 2009 1349Interferon-g and Allogeneic Bone Marrow Transplanta colon adenocarcinoma. The GVL effects were asso-
ciated with high levels of IFN-g from donor NK, and
could be partially abrogated by anti-IFN-g antibody.
In addition, activated NK cells are able to prime DC
to secrete IL-12 and to induce CD8 T cell memory re-
sponse through an IFN-g-dependent pathway [59,60].
However, other experiments demonstrated that DC
activation by NK cells was mediated through direct
cell-to-cell interaction [61]. Thus, donor NK cells se-
creted IFN-g can augment the antitumor activity of
the allograft in direct and indirect mechanisms.
NKTcells have been demonstrated to regulate sup-
pressive responses through local IFN-g production in
transplantation rejection, autoimmune diseases, and
GVHD [62]. In vitro expansion and transplantation
of cytolytic CD81 NKT cells reduced GVHD com-
pared to unfractionated donor splenocytes [6]. Type
II NKT cells that lack Va14 Ja18 expression and are
CD1d-restricted, protect against GVHD in an IFN-
g-dependent way compared to type I Va14 Ja18
TCR1NKT cells [63,64] (Figure 2).
IFN-g expression by CD251CD41 regulatory
T cells
IFN-g is one of the major mediators of the immu-
nosuppressive role of CD251CD41 regulatory T (T
reg) cells [65,66]. Stimulation of ex vivo expanded T
reg cells with alloantigen can induce rapid and transient
IFN-g production, which causes immune suppression
by multiple mechanisms. IFN-g can directly inhibit
T cell activation by inducing apoptosis or retarding T
cell proliferation. IFN-g also acts on APC in close
proximity to T reg limiting their ability to activate T
cells. IFN-g enhances expression of iNOS and IDO,
the release of which will subsequently prevent T cell
proliferation and activation [31]. Several reports have
shown that depletion of T reg cells accelerates
GVHD, and that the addition of T reg cells reduces
GVHD. In a murine BMT model, Negrin et al. [67]
showed that inoculation of donor T reg into tumor-
bearing recipients inhibited expansion of alloreactive
T cells and GVHD. However, the percentage of
IFN-g-producing conventional T cells and serum
IFN-g in mice that received grafts containing T reg
cells were also decreased. The differential effect of
IFN-g secreted by T reg in these models can be ex-
plained by the various roles of IFN-g in different stages
of GVHD. Very early expression of IFN-g by T reg
during the phase of T cell activation could lead to the
initiation of counterregulatory effects that limit the ex-
tent of T cell alloactivity (Figure 1).IFN-g expression by mesenchymal stem cells
(MSCs)
Accumulating data have showed that CD342 fibro-
blast-like MSCs can be potently immunosuppressiveand inhibit GVHD in murine BMT models. More
intriguingly, MSCs expanded ex vivo have been used
to successfully treat ongoing and steroid-refractory
GVHD in clinical trials [68,69]. Mechanisms of sup-
pression of GVHD by MSCs involve their effects on
other immune cells including T cells, APCs, NK cells,
and B cells [70,71]. A recent study from Zhang et al.
[72] showed that MSCs could not only drive immature
DCs or mature DCs to escape from apoptosis, but also
induce mature DCs into a distinct regulatory DC
population capable of inhibiting T cell proliferation,
activity, and IFN-g production through a Jagged-2-
dependent mechanism. Blockade of the IFN-g
pathway, using IFN-g knock-out T cells or IFN-g re-
ceptor-deficientMSCs abolished the immunosuppres-
sive effect of MSCs [71,73]. IFN-g can also stimulate
the production of IDO by MSCs, which in turn, in-
hibited the proliferation of activated T or NK cells
[74]. However, Shi et al. [73] reported that IFN-g is
necessary but not sufficient for the immunosuppressive
function of MSCs. IFN-g must be present along with
any one of three other proinflammatory cytokines,
TNF-a, IL-1a, or IL-1b to induce immunosuppres-
sion byMSCs.More recently, Polchert et al. [75] found
that MSCs, pretreated with IFN-g, were activated and
could suppress GVHD more efficiently than MSCs
that were not activated. The MSC activation was de-
pendent on the magnitude of IFN-g exposure, with in-
creased IFN-g exposure leading to increased MSC
suppression of GVHD. These IFN-g ‘‘activated
MSC’’ present a new strategy for preventing GVHD
using fewer MSC. Taken together, local production
of IFN-g by T reg, NK cells, or activated conventional
T cells may induce host-typeMSC to become activated
and more immunosuppressive, thereby limiting
GVHD. The possibility that MSC may also limit
GVL activity of donor T cells is of some concern, a re-
cent clinical trial of the precaptive administration of
MSCs was characterized by an excess of early leukemia
relapse [76] (Figure 1).Molecular and Cellular Effects of IFN-g
IFN-g limits expansion of allo-reactive T cells
IFN-g can suppress GVHD by inhibiting activa-
tion and expansion of both donor CD41 and
CD81 T cells by inducing apoptosis and cell cycle ar-
rest [22,77]. The mechanism of alloreactive T cell ap-
optosis induced by IFN-g in transplant models is not
completely clear. In vitro studies have indicated that
upon IFN-g treatment, FAS is upregulated and acti-
vated to induce apoptosis in a series of cell lines
[78,79]. In vivo studies have consistently shown that
IFN-g regulates expression of both FAS/FASL on al-
loreactive donor T cells. In addition, many other IFN-
g-regulated genes, including IDO on APC, were also
Figure 1. IFN-g-producing cells show different effects on GVHD and
GVL.4 increase;. inhibit; ? unknown.
Figure 2. Role of IFN-g during the development of GVHD and GVL.
The conditioning regimen leads to damage of host tissues and allows
the translocation of LPS and other pro-inflammatory cytokines into
the circulation, leading to the activation of donor T cells by host APC
[17]. Interaction between donor IL-12-producing APC with donor T
cells can increase the IFN-g production by activated T cells. High local
levels of IFN-g subsequently induce IDO expression on donor APC
(Lu et al., 2009, in preparation). IDO1 APCs help maintain the tolerant
phenotype of T-reg, which inhibits the Th1 and Th17 polarization of do-
nor T cells, resulting in downmodulation of T cell alloreactivity and
GVHD effect [83].
1350 Biol Blood Marrow Transplant 15:1347-1353, 2009Y. Lu and E. K. Wallerfound to be involved in IFN-g-induced apoptosis and
will be discussed shortly.
Global gene expression profiles of livers after ex-
perimental allogeneic and syngeneic BMT using oli-
gonucleotide microarray showed upregulation of
IFN-g-inducible genes, including MHC class II mol-
ecules, and genes related to leukocyte trafficking at day
7 prior to the development of GVHD. At day 35 after
allogeneic BMT, when hepatic GVHD was histologi-
cally evident, genes related to cellular effectors and
acute-phase proteins were upregulated, whereas genes
largely related to metabolism and endocrine function
were downregulated [80]. These data suggested that
the temporal sequence of increased expression of genes
associated with the attraction and activation of donor
T cells induced by IFN-g early after BMT is important
in the initiation of GVHD.
IFN-g induces IDO expression in APC and host
epithelial cells
IDO is an intracellular heme-containing enzyme
that catalyzes the essential amino acid tryptophan.
IDO gene can be prominently upregulated by IFN-g
in a promoter-dependent way through STAT1 and
IRF-1 binding sites (GAS and ISRE) or by activation
of PI3K, JNK, or NF-kB [31,81]. Broad evidence
supports IDO as an important mediator of peripheral
tolerance induced by IFN-g. IDO-mediated immuno-
suppression includes depletion of tryptophan in the
microenvironment and local secretion of the products
of tryptophan metabolism that have direct immuno-
suppressive effects. For instance, kynurenine and 3-
hydroxykynurenine are cytotoxic to human T cells,B, and NK cells. Other metabolic products 3-hydrox-
yanthranilic acid and quinolinic acid are able to induce
Th1 cell apoptosis [31,82]. In addition, IDO can also
help maintaining T regs in their normal suppressive
phenotype [83] (Figure 2). Interestingly, a recent study
showed that transgenic expression of IDO resulted in
increased tubular epithelial cell apoptosis in a FAS/
FASL-dependent, caspase-8-mediated mechanism,
suggesting that integration of a network of IFN-g-
regulated pathways can result in counterregulatory
effects including cell death [84]. Based on these inter-
esting findings, use of a small molecule inhibitor of
IDO D1-MT to reverse the immunosuppression, has
entered a phase I clinical trial.
By using IDO knockout mice as recipients, Jasper-
son and colleagues [85] demonstrated that without
host IDO expression, mice experienced markedly
higher GVHD morbidity, suggesting that IDO can
act at sites of GVHD to decrease T cell proliferation.
Thus, modulation of IDO synthesis in GVHD target
organs may represent an interesting strategy for limit-
ing gut GVHD. Intriguingly, a recent clinical study
showed that DCs and monocytes fromHPCT patients
developing aGVHD were less able to upregulate IDO
on exposure to IFN-g than healthy volunteers or those
with milder GVHD [86]. However, the mechanism of
IDO expression in DC on the regulation of T cell al-
loactivity during GVHD is not completely under-
stood. Recently, using a murine transplant model, we
Figure 3. IFN-g-induced IDO expression on host epithelial cells inhibits GVHD. Donor T cells induce GVHD effects that cause target epithelial cell
apoptosis [17,22]. IDO expression on host epithelial cells induced by IFN-g from donor T cells inhibits GVHD [85]. In addition, IFN-g enhances GVL
effect through both direct and indirect mechanisms, resulting in apoptosis of tumor cells [18].
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lation of IDO in DCs, suggesting that time and tissue-
dependent IFN-g synthesis by donor T cells may
initiate counterregulatory immune mechanisms that
limit overall GVHD activity, whereas it permits selec-
tive GVL effects (Figures 2 and 3).CONCLUSION
The dual effects of IFN-g on GVHD and GVL
make understanding the role of local production of
IFN-g during the initial interaction of donor T cells
and NK cells with host- and donor-type APC critical
to achieve the goal of separating GVL from GVHD.
The effects of IFN-g are dependent upon local con-
centrations in the lymph node or epithelial micro-
environments, the timing of synthesis or exogenous
administration, and the stage of the development of
the allo immune response in transplants. However,
much remains unknown about the precise pathways
of IFN-g action and the reciprocal actions of IFN-g
derived from different cell subsets. Another challenge
is to understand the mechanisms by which IFN-g sig-
naling and cellular effects integrate with other cyto-
kines, because cells in vivo are not exposed to a single
stimulus in isolation. Better murine models and analy-
sis of local effects of the cytokine mileau on T cells at
multiple time points and tissue sites in the first few
hours and days after clinical allogeneic HPCT will
help elucidate the role of IFN-g in inducing GVL ac-
tivities while limiting GVHD. Understanding of these
questions should lead to the development of novel
strategies for patients undergoing BMT to maximize
GVL with limited GVHD.ACKNOWLEDGMENTS
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